The Relative Strength (RS) Rating for Arcellx climbed into a new percentile Tuesday, as it got a lift from 66 to 73.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's unique RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the last 52 weeks matched up against all other stocks.
Decades of market research reveals that the stocks that go on to make the biggest gains tend to have an RS Rating of above 80 as they launch their biggest runs. See if Arcellx can continue to rebound and clear that threshold.
While Arcellx is not near an ideal buy point right now, see if it goes on to form and break out from a proper chart pattern.
The company posted 0% earnings growth in its most recent report, while sales growth came in at -79%. Look for the next report on or around Aug. 18.
Arcellx earns the No. 301 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Incyte and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
